Biao Luo,Hiu Wing Cheung,Aravind Subramanian,Tanaz Sharifnia,Michael Okamoto,Xiaoping Yang,Greg Hinkle,Jesse S. Boehm,Rameen Beroukhim,Barbara A. Weir,Craig Mermel,David A. Barbie,Tarif Awad,Xiaochuan Zhou,Tuyen Nguyen,Bruno Piqani,Cheng Li,Todd R. Golub,Matthew Meyerson,Nir Hacohen,William C. Hahn,Eric S. Lander,David M. Sabatini,David E. Root

Abstract:More complete knowledge of the molecular mechanisms underlying cancer will improve prevention, diagnosis and treatment. Efforts such as The Cancer Genome Atlas are systematically characterizing the structural basis of cancer, by identifying the genomic mutations associated with each cancer type. A powerful complementary approach is to systematically characterize the functional basis of cancer, by identifying the genes essential for growth and related phenotypes in different cancer cells. Such information would be particularly valuable for identifying potential drug targets. Here, we report the development of an efficient, robust approach to perform genome-scale pooled shRNA screens for both positive and negative selection and its application to systematically identify cell essential genes in 12 cancer cell lines. By integrating these functional data with comprehensive genetic analyses of primary human tumors, we identified known and putative oncogenes such as EGFR , KRAS , MYC , BCR-ABL , MYB , CRKL , and CDK4 that are essential for cancer cell proliferation and also altered in human cancers. We further used this approach to identify genes involved in the response of cancer cells to tumoricidal agents and found 4 genes required for the response of CML cells to imatinib treatment: PTPN1 , NF1 , SMARCB1 , and SMARCE1 , and 5 regulators of the response to FAS activation, FAS, FADD, CASP8, ARID1A and CBX1. Broad application of this highly parallel genetic screening strategy will not only facilitate the rapid identification of genes that drive the malignant state and its response to therapeutics but will also enable the discovery of genes that participate in any biological process.

Bioinformatics and cancer target discovery

Using Bioinformatics for Drug Target Identification from the Genome

[Bioinformatics of Tumor Molecular Targets from Big Data].

Bioinformatics approaches for anti-cancer drug discovery.

Bioinformatics tools and resources for cancer and application

Identifying targets for drug discovery using bioinformatics

Discovery of novel therapeutic targets in cancer using patient-specific gene regulatory networks

Bioinformatics for cancer immunotherapy target discovery

A Comprehensive Review of Bioinformatics Tools for Genomic Biomarker Discovery Driving Precision Oncology

Microarray bioinformatics in cancer- a review

Advances in Proteomics and Bioinformatics

Effectively utilizing publicly available databases for cancer target evaluation

Discovery of therapeutic targets in cancer using chromatin accessibility and transcriptomic data

Big data in basic and translational cancer research

Targeting Tumor Suppressor Genes for Cancer Therapy

Target Discovery and Validation in the Post-Genomic Era

Highly parallel identification of essential genes in cancer cells

Target discovery from data mining approaches

Analytical Methods for Inferring Functional Effects of Single Base Pair Substitutions in Human Cancers

Comprehensive Analysis Of Cancer Drugs Based On Human Protein-Protein Interaction Network Profiles Of These Targets

Artificial intelligence in cancer target identification and drug discovery